AhTong的个人主页 - 老虎社区

AhTong

AhTong

暂无个人介绍

IP属地：未知

274关注

5粉丝

0主题

0勋章

2021-11-24

Invest with precaution

抱歉，原内容已删除

2021-11-13

Pfizer continue to grow

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>

2021-10-30

Thanks

抱歉，原内容已删除

2021-10-06

Great

抱歉，原内容已删除

2021-09-10

Like

抱歉，原内容已删除

2021-09-22

trade with caution

抱歉，原内容已删除

2021-11-01

Hope is a good month for stocks

What's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote>

2021-10-06

Rise

抱歉，原内容已删除

2021-10-25

Watch closely

抱歉，原内容已删除

2021-08-29

Up up up

Apple Stock: How It Could Be A Great Inflation Play<blockquote>苹果股票：它如何成为一场伟大的通胀游戏</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583403892979837","uuid":"3583403892979837","gmtCreate":1620311655312,"gmtModify":1630461442704,"name":"AhTong","pinyin":"ahtong","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":274,"tweetSize":35,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":605479235,"gmtCreate":1639233913158,"gmtModify":1639233913278,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"精辟分析[Like]&nbsp;","listText":"精辟分析[Like]&nbsp;","text":"精辟分析[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605479235","repostId":"605817332","repostType":1,"repost":{"id":605817332,"gmtCreate":1639144226637,"gmtModify":1639159678960,"author":{"id":"3534325775447717","authorId":"3534325775447717","name":"StockCurry","avatar":"https://static.tigerbbs.com/f7eef9aa09efb837ae9c0226b09744f9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3534325775447717","idStr":"3534325775447717"},"themes":[],"title":"美联储Taper(缩减)，加息和量化宽松QE对股市和经济的影响","htmlText":"美联储的鲍威尔最近在听证会中表示会加快缩紧量化宽松政策，也就是我们常听到的 Tapering, 这直接导致股市大幅下跌，而且从历史来看基本每次要 tapering 的时候都会对股市造成不小的波动。那么具体什么是 Tapering, 他和加息之间又是什么关系，对股市有什么影响，今天我就给大家讲一讲。要想说明白 Tapering 和加息，我们就需要简单的讲一下经济是怎样运行的。首先经济是由交易组成的，也就是我们用钱或信用来向另一方买卖商品，服务或金融资产。经济就是无数交易的总和。除了我们个人会进行交易之外，企业，银行和政府也同样在以上述方式进行交易。其中政府是最大的买方和卖方。政府又分为中央政府和中央银行也就是美联储，美联储通过影响利率和发行货币来控制货币和信贷数量，从而达到稳定经济的效果。中央政府可以购买商品和服务，可以向人民发钱，但是无法发行货币。另一个在经济中比较重要的概念是信贷，也就我们说的借钱。比如我们要买房或买车，但是钱不够，我们可以通过向银行借钱来增加自己的购买力，这里我们就是借款人，银行就是贷款人。借款人保证会还贷款，也就是本金，同时向银行支付一定的利息。利率高时我们通常会比较少借钱，因为代款会变的昂贵，如果利率低时，借钱就会增加。如果我们可以保证在一定的时间里会偿还借的钱，并且银行相信我们这个承诺，那信贷就产生了。信贷之所以是经济中最重要的组成部分主要是因为我们能通过信贷增加自己的购买力，同时也产生了债务周期，债务周期有点超纲，今天我们就不在这讨论了。在 2020 年疫情到来的时候，很多人失业，收入急剧下降，使得他们的债务急剧上升，这时候政府就需要救济，所以采用了量化宽松政策，也就是我们所说的 QE，用普通话说就是由美联储发行货币。现在随着数字时代的发展，美联储已经不会再去印纸币了，而是像我们玩游戏时作弊一样，给自己在” 后台 “账户里加入了 N 个 0，这样","listText":"美联储的鲍威尔最近在听证会中表示会加快缩紧量化宽松政策，也就是我们常听到的 Tapering, 这直接导致股市大幅下跌，而且从历史来看基本每次要 tapering 的时候都会对股市造成不小的波动。那么具体什么是 Tapering, 他和加息之间又是什么关系，对股市有什么影响，今天我就给大家讲一讲。要想说明白 Tapering 和加息，我们就需要简单的讲一下经济是怎样运行的。首先经济是由交易组成的，也就是我们用钱或信用来向另一方买卖商品，服务或金融资产。经济就是无数交易的总和。除了我们个人会进行交易之外，企业，银行和政府也同样在以上述方式进行交易。其中政府是最大的买方和卖方。政府又分为中央政府和中央银行也就是美联储，美联储通过影响利率和发行货币来控制货币和信贷数量，从而达到稳定经济的效果。中央政府可以购买商品和服务，可以向人民发钱，但是无法发行货币。另一个在经济中比较重要的概念是信贷，也就我们说的借钱。比如我们要买房或买车，但是钱不够，我们可以通过向银行借钱来增加自己的购买力，这里我们就是借款人，银行就是贷款人。借款人保证会还贷款，也就是本金，同时向银行支付一定的利息。利率高时我们通常会比较少借钱，因为代款会变的昂贵，如果利率低时，借钱就会增加。如果我们可以保证在一定的时间里会偿还借的钱，并且银行相信我们这个承诺，那信贷就产生了。信贷之所以是经济中最重要的组成部分主要是因为我们能通过信贷增加自己的购买力，同时也产生了债务周期，债务周期有点超纲，今天我们就不在这讨论了。在 2020 年疫情到来的时候，很多人失业，收入急剧下降，使得他们的债务急剧上升，这时候政府就需要救济，所以采用了量化宽松政策，也就是我们所说的 QE，用普通话说就是由美联储发行货币。现在随着数字时代的发展，美联储已经不会再去印纸币了，而是像我们玩游戏时作弊一样，给自己在” 后台 “账户里加入了 N 个 0，这样","text":"美联储的鲍威尔最近在听证会中表示会加快缩紧量化宽松政策，也就是我们常听到的 Tapering, 这直接导致股市大幅下跌，而且从历史来看基本每次要 tapering 的时候都会对股市造成不小的波动。那么具体什么是 Tapering, 他和加息之间又是什么关系，对股市有什么影响，今天我就给大家讲一讲。要想说明白 Tapering 和加息，我们就需要简单的讲一下经济是怎样运行的。首先经济是由交易组成的，也就是我们用钱或信用来向另一方买卖商品，服务或金融资产。经济就是无数交易的总和。除了我们个人会进行交易之外，企业，银行和政府也同样在以上述方式进行交易。其中政府是最大的买方和卖方。政府又分为中央政府和中央银行也就是美联储，美联储通过影响利率和发行货币来控制货币和信贷数量，从而达到稳定经济的效果。中央政府可以购买商品和服务，可以向人民发钱，但是无法发行货币。另一个在经济中比较重要的概念是信贷，也就我们说的借钱。比如我们要买房或买车，但是钱不够，我们可以通过向银行借钱来增加自己的购买力，这里我们就是借款人，银行就是贷款人。借款人保证会还贷款，也就是本金，同时向银行支付一定的利息。利率高时我们通常会比较少借钱，因为代款会变的昂贵，如果利率低时，借钱就会增加。如果我们可以保证在一定的时间里会偿还借的钱，并且银行相信我们这个承诺，那信贷就产生了。信贷之所以是经济中最重要的组成部分主要是因为我们能通过信贷增加自己的购买力，同时也产生了债务周期，债务周期有点超纲，今天我们就不在这讨论了。在 2020 年疫情到来的时候，很多人失业，收入急剧下降，使得他们的债务急剧上升，这时候政府就需要救济，所以采用了量化宽松政策，也就是我们所说的 QE，用普通话说就是由美联储发行货币。现在随着数字时代的发展，美联储已经不会再去印纸币了，而是像我们玩游戏时作弊一样，给自己在” 后台 “账户里加入了 N 个 0，这样","images":[{"img":"https://static.tigerbbs.com/040cac902bdd2e75252e968c9aa132bc","width":"1024","height":"683"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605817332","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":6,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874523915,"gmtCreate":1637803062915,"gmtModify":1637803062978,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>股王当之无愧","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>股王当之无愧","text":"$Apple(AAPL)$股王当之无愧","images":[{"img":"https://static.tigerbbs.com/c825e57efcfd29e20187bda0faf93c20","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874523915","isVote":1,"tweetType":1,"viewCount":2698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":874076607,"gmtCreate":1637716284407,"gmtModify":1637716284407,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Invest with precaution","listText":"Invest with precaution","text":"Invest with precaution","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/874076607","repostId":"1119695149","repostType":4,"isVote":1,"tweetType":1,"viewCount":3142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871366962,"gmtCreate":1637027207336,"gmtModify":1637027225838,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Fellow closely","listText":"Fellow closely","text":"Fellow closely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871366962","repostId":"1118366658","repostType":4,"isVote":1,"tweetType":1,"viewCount":2862,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873057856,"gmtCreate":1636810156651,"gmtModify":1636810156651,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Pfizer continue to grow&nbsp;","listText":"Pfizer continue to grow&nbsp;","text":"Pfizer continue to grow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873057856","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845010890,"gmtCreate":1636251799974,"gmtModify":1636251800144,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"好消息,疫情止股市漲","listText":"好消息,疫情止股市漲","text":"好消息,疫情止股市漲","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845010890","repostId":"842415468","repostType":1,"repost":{"id":842415468,"gmtCreate":1636172640000,"gmtModify":1636249022463,"author":{"id":"9000000000000034","authorId":"9000000000000034","name":"投资银行在线","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000034","idStr":"9000000000000034"},"themes":[],"title":"辉瑞口服抗新冠药来了，高危患者住院、死亡风险直降89%","htmlText":"新冠疫苗又有大消息，第二款口服药来了：辉瑞称其在研口服新冠药物可减少高危新冠患者大约89%的住院与死亡风险~！ 辉瑞口服抗新冠药来了 高危患者住院、死亡风险直降89%！ 辉瑞11月5日宣布了其在研的口服新冠候选药物Paxlovid的最新研究结果，结果显示，Paxlovid可以减少高达89%的新冠肺炎非住院患者的住院或死亡率。其中，治疗组住院或死亡率为仅为0.8%（389例中3例住院，无死亡），安慰剂组住院或死亡率则为7%（385例中27例住院，其中7例随后死亡）。 辉瑞公司表示，对研究结果的初步观察表明，其实验性抗新冠药物Paxlovid使高危新冠患者的住院和死亡风险减少89%。 辉瑞称，因为上述临床试验结果显示出“压倒性的疗效”，根据独立数据监测委员会的建议并与FDA协商后，辉瑞将停止上述药物的进一步纳入研究，并计划将数据作为其一部分提交正在尽快向FDA滚动提交紧急使用授权 (EUA)。 辉瑞表示，将通过基于每个国家的收入水平的分层定价方法提供Paxlovid，以促进全球范围内的公平获取。高收入和中高收入国家将比低收入国家支付更多费用。 辉瑞执行长博尔拉（Albert Bourla）说：「在全球致力遏制疫情肆虐下，今天的消息是真正的扭转局势消息。」 博尔拉指出：「这些数据显示，若获得监管机构批准或授权，我们的口服抗病毒候选药物可能挽救患者的性命，降低感染COVID-19的重症程度，并消除多达约90%住院治疗。」 美国总统拜登表示，辉瑞的抗新冠药物非常有希望，辉瑞的抗新冠药物可以“大幅降低”因新冠肺炎住院和死亡的风险。 辉瑞股价暴增 其他厂商跌惨了 受消息影响，美股辉瑞大涨超8% 因辉瑞新冠药物疗效显著，竞争对手默沙东和部分疫苗股下跌。 兴证医药分析称，默沙东新冠药物Molnupiravir已于近日在英国获批，其对轻中症患者的疗效为降低住院和死亡风险50%，药物相关不良反应","listText":"新冠疫苗又有大消息，第二款口服药来了：辉瑞称其在研口服新冠药物可减少高危新冠患者大约89%的住院与死亡风险~！ 辉瑞口服抗新冠药来了 高危患者住院、死亡风险直降89%！ 辉瑞11月5日宣布了其在研的口服新冠候选药物Paxlovid的最新研究结果，结果显示，Paxlovid可以减少高达89%的新冠肺炎非住院患者的住院或死亡率。其中，治疗组住院或死亡率为仅为0.8%（389例中3例住院，无死亡），安慰剂组住院或死亡率则为7%（385例中27例住院，其中7例随后死亡）。 辉瑞公司表示，对研究结果的初步观察表明，其实验性抗新冠药物Paxlovid使高危新冠患者的住院和死亡风险减少89%。 辉瑞称，因为上述临床试验结果显示出“压倒性的疗效”，根据独立数据监测委员会的建议并与FDA协商后，辉瑞将停止上述药物的进一步纳入研究，并计划将数据作为其一部分提交正在尽快向FDA滚动提交紧急使用授权 (EUA)。 辉瑞表示，将通过基于每个国家的收入水平的分层定价方法提供Paxlovid，以促进全球范围内的公平获取。高收入和中高收入国家将比低收入国家支付更多费用。 辉瑞执行长博尔拉（Albert Bourla）说：「在全球致力遏制疫情肆虐下，今天的消息是真正的扭转局势消息。」 博尔拉指出：「这些数据显示，若获得监管机构批准或授权，我们的口服抗病毒候选药物可能挽救患者的性命，降低感染COVID-19的重症程度，并消除多达约90%住院治疗。」 美国总统拜登表示，辉瑞的抗新冠药物非常有希望，辉瑞的抗新冠药物可以“大幅降低”因新冠肺炎住院和死亡的风险。 辉瑞股价暴增 其他厂商跌惨了 受消息影响，美股辉瑞大涨超8% 因辉瑞新冠药物疗效显著，竞争对手默沙东和部分疫苗股下跌。 兴证医药分析称，默沙东新冠药物Molnupiravir已于近日在英国获批，其对轻中症患者的疗效为降低住院和死亡风险50%，药物相关不良反应","text":"新冠疫苗又有大消息，第二款口服药来了：辉瑞称其在研口服新冠药物可减少高危新冠患者大约89%的住院与死亡风险~！ 辉瑞口服抗新冠药来了 高危患者住院、死亡风险直降89%！ 辉瑞11月5日宣布了其在研的口服新冠候选药物Paxlovid的最新研究结果，结果显示，Paxlovid可以减少高达89%的新冠肺炎非住院患者的住院或死亡率。其中，治疗组住院或死亡率为仅为0.8%（389例中3例住院，无死亡），安慰剂组住院或死亡率则为7%（385例中27例住院，其中7例随后死亡）。 辉瑞公司表示，对研究结果的初步观察表明，其实验性抗新冠药物Paxlovid使高危新冠患者的住院和死亡风险减少89%。 辉瑞称，因为上述临床试验结果显示出“压倒性的疗效”，根据独立数据监测委员会的建议并与FDA协商后，辉瑞将停止上述药物的进一步纳入研究，并计划将数据作为其一部分提交正在尽快向FDA滚动提交紧急使用授权 (EUA)。 辉瑞表示，将通过基于每个国家的收入水平的分层定价方法提供Paxlovid，以促进全球范围内的公平获取。高收入和中高收入国家将比低收入国家支付更多费用。 辉瑞执行长博尔拉（Albert Bourla）说：「在全球致力遏制疫情肆虐下，今天的消息是真正的扭转局势消息。」 博尔拉指出：「这些数据显示，若获得监管机构批准或授权，我们的口服抗病毒候选药物可能挽救患者的性命，降低感染COVID-19的重症程度，并消除多达约90%住院治疗。」 美国总统拜登表示，辉瑞的抗新冠药物非常有希望，辉瑞的抗新冠药物可以“大幅降低”因新冠肺炎住院和死亡的风险。 辉瑞股价暴增 其他厂商跌惨了 受消息影响，美股辉瑞大涨超8% 因辉瑞新冠药物疗效显著，竞争对手默沙东和部分疫苗股下跌。 兴证医药分析称，默沙东新冠药物Molnupiravir已于近日在英国获批，其对轻中症患者的疗效为降低住院和死亡风险50%，药物相关不良反应","images":[{"img":"https://static.tigerbbs.com/2888b3dc662143688b3f7198593c83a8","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/5159a15302614108a0a1546979ea3eb7","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/a1682802d50d4d56a318fe33571ca276","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842415468","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845036840,"gmtCreate":1636251417609,"gmtModify":1636251417776,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BAC\">$Bank of America(BAC)$</a>Earning opporunity","listText":"<a href=\"https://laohu8.com/S/BAC\">$Bank of America(BAC)$</a>Earning opporunity","text":"$Bank of America(BAC)$Earning opporunity","images":[{"img":"https://static.tigerbbs.com/69ffbd888c8841e070a1f4a21ce9a43e","width":"1080","height":"3478"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845036840","isVote":1,"tweetType":1,"viewCount":2398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842590615,"gmtCreate":1636194241322,"gmtModify":1636194241474,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Effective pill, stocks rise","listText":"Effective pill, stocks rise","text":"Effective pill, stocks rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842590615","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":2674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843891164,"gmtCreate":1635816002377,"gmtModify":1635816002377,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Looking forward to it","listText":"Looking forward to it","text":"Looking forward to it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843891164","repostId":"2180201393","repostType":4,"isVote":1,"tweetType":1,"viewCount":3380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843806557,"gmtCreate":1635815750006,"gmtModify":1635815750006,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843806557","repostId":"2180209403","repostType":4,"isVote":1,"tweetType":1,"viewCount":3250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843175030,"gmtCreate":1635815450296,"gmtModify":1635815450296,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Wilmar is a strong stock","listText":"Wilmar is a strong stock","text":"Wilmar is a strong stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843175030","repostId":"2180720500","repostType":4,"isVote":1,"tweetType":1,"viewCount":1457,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849102179,"gmtCreate":1635732550275,"gmtModify":1635732550326,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Hope is a good month for stocks","listText":"Hope is a good month for stocks","text":"Hope is a good month for stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849102179","repostId":"1150912013","repostType":4,"repost":{"id":"1150912013","kind":"news","pubTimestamp":1635724788,"share":"https://www.laohu8.com/m/news/1150912013?lang=zh_CN&edition=full","pubTime":"2021-11-01 07:59","market":"us","language":"en","title":"What's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1150912013","media":"finance.yahoo","summary":"The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.“November is t","content":"<p>The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.</p><p><blockquote>如果历史有任何迹象的话，股市创纪录的走势将在未来几周内获得动力。</blockquote></p><p> The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.</p><p><blockquote>假期的开始通常是华尔街一年中的强劲时期，分析师指出，这种模式是保持乐观的理由，即股市在经历了动荡的9月份后将保持在历史高点。</blockquote></p><p> Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.</p><p><blockquote>根据LPL Financial的数据，从历史上看，11月一直是股市一年中表现最好的月份——无论是自1950年以来还是过去十年。</blockquote></p><p> That’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.</p><p><blockquote>这还不是全部。根据股票交易者年鉴，历史表明股市最强劲的六个月是11月至4月。11月也是市场最好的三个月（11月至1月）的第一个月。</blockquote></p><p> Why is November the best?</p><p><blockquote>为什么11月是最好的？</blockquote></p><p> This seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.</p><p><blockquote>这种季节性强势是由多种因素共同造成的。一方面，根据LPL Financial的数据，一年中的最后三个月通常是股市最好的月份，股市平均上涨3.8%。</blockquote></p><p> Strong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.</p><p><blockquote>购物者在假期期间的强劲支出也往往会转化为以消费者为中心的企业的强劲季度。一些分析师还将其归因于假期期间的乐观情绪、年终投资组合调整以及投资者正在度假。</blockquote></p><p> “November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”</p><p><blockquote>LPL Financial首席市场策略师瑞安·德特里克(Ryan Detrick)在给客户的一份报告中表示：“11月是一年中最好的月份，但它似乎并没有你想象的那么受欢迎。”“我们都认为12月是最好的月份，但11月实际上更好，而且很少大张旗鼓。也许这应该是多头的月份，而不是火鸡的月份。”</blockquote></p><p> Wall Street avoids spooky October</p><p><blockquote>华尔街避免幽灵般的十月</blockquote></p><p> While October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.</p><p><blockquote>虽然10月份对投资者来说通常被认为是一个幽灵般的月份，在1929年、1987年的崩盘和2008年全球金融危机期间赢得了坏名声，但今年投资者并没有那么害怕。</blockquote></p><p> After the S&amp;P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.</p><p><blockquote>在标普500 9月份录得自冠状病毒大流行开始以来的最大月度跌幅后，由于有进一步迹象表明企业利润在去年衰退后再次增长，该指数在10月份反弹了6%以上。</blockquote></p><p> “It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.</p><p><blockquote>《股票交易者年鉴》编辑杰夫·赫希(Jeff Hirsch)在给客户的一份报告中表示：“看起来市场已经抵制了‘十月恐惧症’，避免了令人恐惧的崩盘或大屠杀，这些崩盘或大屠杀给这个月带来了坏名声。”</blockquote></p><p> To be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.</p><p><blockquote>可以肯定的是，11月份在熊市期间遭受了打击，主要股指较近期峰值下跌了20%以上。</blockquote></p><p> For instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred</p><p><blockquote>例如，根据股票交易者年鉴，2000年11月是纳斯达克综合指数有记录以来第二糟糕的月份，以科技为重点的指数暴跌近23%。只有1987年10月更糟糕，那是“黑色星期一”股灾发生的时候</blockquote></p><p> Why investors should be optimistic</p><p><blockquote>为什么投资者应该乐观</blockquote></p><p> The U.S. economy&nbsp;slowed substantially from July through September&nbsp;following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.</p><p><blockquote>在经历了一系列障碍后，美国经济从7月到9月大幅放缓，包括COVID-19病例激增、供应链瓶颈、消费者价格上涨以及联邦刺激措施效果减弱。</blockquote></p><p> But with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.</p><p><blockquote>但随着新冠肺炎病例的下降和疫苗接种的增加，大多数经济学家认为，在从大流行引发的衰退中仍然强劲的复苏中，疲软表现出疲软，预计今年最后几个月将出现健康反弹。</blockquote></p><p> There are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.</p><p><blockquote>有迹象表明，由于强劲的季节性趋势、好于预期的企业盈利以及COVID-19病例下降，今年最后几个月华尔街可能会出现更多上涨。市场广度也有所改善，这意味着更多股票参与涨势，这是市场健康强劲的标志。</blockquote></p><p> Jobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.</p><p><blockquote>最近几周，申请失业救济人数也在稳步下降，最近申请失业救济人数自冠状病毒大流行开始以来首次降至250万以下。</blockquote></p><p> After suffering its first 5% pullback of 2021 in early October, the S&amp;P 500 has come roaring back and closed at a record high on October 21. The S&amp;P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.</p><p><blockquote>在10月初经历了2021年首次5%的回调后，标普500卷土重来，并于10月21日收于历史新高。标普500指数今年迄今已上涨超过20%，一路上创下50多个历史新高。</blockquote></p><p> That could be a positive sign for investors in the coming months. The past seven times the S&amp;P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.</p><p><blockquote>这对未来几个月的投资者来说可能是一个积极的信号。LPL Financial的数据显示，过去七次标普500在第四季度之前上涨了15%，最后一个季度每次都上涨了5.8%。</blockquote></p><p> “We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.</p><p><blockquote>德特里克表示：“我们坚信，新高是值得拥抱的，而不是害怕的，历史表明，新高往往会成群结队地出现——今年到目前为止，情况确实如此。”</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">finance.yahoo</strong><span class=\"h-time small\">2021-11-01 07:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.</p><p><blockquote>如果历史有任何迹象的话，股市创纪录的走势将在未来几周内获得动力。</blockquote></p><p> The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.</p><p><blockquote>假期的开始通常是华尔街一年中的强劲时期，分析师指出，这种模式是保持乐观的理由，即股市在经历了动荡的9月份后将保持在历史高点。</blockquote></p><p> Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.</p><p><blockquote>根据LPL Financial的数据，从历史上看，11月一直是股市一年中表现最好的月份——无论是自1950年以来还是过去十年。</blockquote></p><p> That’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.</p><p><blockquote>这还不是全部。根据股票交易者年鉴，历史表明股市最强劲的六个月是11月至4月。11月也是市场最好的三个月（11月至1月）的第一个月。</blockquote></p><p> Why is November the best?</p><p><blockquote>为什么11月是最好的？</blockquote></p><p> This seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.</p><p><blockquote>这种季节性强势是由多种因素共同造成的。一方面，根据LPL Financial的数据，一年中的最后三个月通常是股市最好的月份，股市平均上涨3.8%。</blockquote></p><p> Strong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.</p><p><blockquote>购物者在假期期间的强劲支出也往往会转化为以消费者为中心的企业的强劲季度。一些分析师还将其归因于假期期间的乐观情绪、年终投资组合调整以及投资者正在度假。</blockquote></p><p> “November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”</p><p><blockquote>LPL Financial首席市场策略师瑞安·德特里克(Ryan Detrick)在给客户的一份报告中表示：“11月是一年中最好的月份，但它似乎并没有你想象的那么受欢迎。”“我们都认为12月是最好的月份，但11月实际上更好，而且很少大张旗鼓。也许这应该是多头的月份，而不是火鸡的月份。”</blockquote></p><p> Wall Street avoids spooky October</p><p><blockquote>华尔街避免幽灵般的十月</blockquote></p><p> While October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.</p><p><blockquote>虽然10月份对投资者来说通常被认为是一个幽灵般的月份，在1929年、1987年的崩盘和2008年全球金融危机期间赢得了坏名声，但今年投资者并没有那么害怕。</blockquote></p><p> After the S&amp;P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.</p><p><blockquote>在标普500 9月份录得自冠状病毒大流行开始以来的最大月度跌幅后，由于有进一步迹象表明企业利润在去年衰退后再次增长，该指数在10月份反弹了6%以上。</blockquote></p><p> “It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.</p><p><blockquote>《股票交易者年鉴》编辑杰夫·赫希(Jeff Hirsch)在给客户的一份报告中表示：“看起来市场已经抵制了‘十月恐惧症’，避免了令人恐惧的崩盘或大屠杀，这些崩盘或大屠杀给这个月带来了坏名声。”</blockquote></p><p> To be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.</p><p><blockquote>可以肯定的是，11月份在熊市期间遭受了打击，主要股指较近期峰值下跌了20%以上。</blockquote></p><p> For instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred</p><p><blockquote>例如，根据股票交易者年鉴，2000年11月是纳斯达克综合指数有记录以来第二糟糕的月份，以科技为重点的指数暴跌近23%。只有1987年10月更糟糕，那是“黑色星期一”股灾发生的时候</blockquote></p><p> Why investors should be optimistic</p><p><blockquote>为什么投资者应该乐观</blockquote></p><p> The U.S. economy&nbsp;slowed substantially from July through September&nbsp;following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.</p><p><blockquote>在经历了一系列障碍后，美国经济从7月到9月大幅放缓，包括COVID-19病例激增、供应链瓶颈、消费者价格上涨以及联邦刺激措施效果减弱。</blockquote></p><p> But with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.</p><p><blockquote>但随着新冠肺炎病例的下降和疫苗接种的增加，大多数经济学家认为，在从大流行引发的衰退中仍然强劲的复苏中，疲软表现出疲软，预计今年最后几个月将出现健康反弹。</blockquote></p><p> There are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.</p><p><blockquote>有迹象表明，由于强劲的季节性趋势、好于预期的企业盈利以及COVID-19病例下降，今年最后几个月华尔街可能会出现更多上涨。市场广度也有所改善，这意味着更多股票参与涨势，这是市场健康强劲的标志。</blockquote></p><p> Jobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.</p><p><blockquote>最近几周，申请失业救济人数也在稳步下降，最近申请失业救济人数自冠状病毒大流行开始以来首次降至250万以下。</blockquote></p><p> After suffering its first 5% pullback of 2021 in early October, the S&amp;P 500 has come roaring back and closed at a record high on October 21. The S&amp;P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.</p><p><blockquote>在10月初经历了2021年首次5%的回调后，标普500卷土重来，并于10月21日收于历史新高。标普500指数今年迄今已上涨超过20%，一路上创下50多个历史新高。</blockquote></p><p> That could be a positive sign for investors in the coming months. The past seven times the S&amp;P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.</p><p><blockquote>这对未来几个月的投资者来说可能是一个积极的信号。LPL Financial的数据显示，过去七次标普500在第四季度之前上涨了15%，最后一个季度每次都上涨了5.8%。</blockquote></p><p> “We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.</p><p><blockquote>德特里克表示：“我们坚信，新高是值得拥抱的，而不是害怕的，历史表明，新高往往会成群结队地出现——今年到目前为止，情况确实如此。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html\">finance.yahoo</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150912013","content_text":"The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.\nThe start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.\nHistorically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.\nThat’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.\nWhy is November the best?\nThis seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.\nStrong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.\n“November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”\nWall Street avoids spooky October\nWhile October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.\nAfter the S&P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.\n“It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.\nTo be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.\nFor instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred\nWhy investors should be optimistic\nThe U.S. economy slowed substantially from July through September following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.\nBut with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.\nThere are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.\nJobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.\nAfter suffering its first 5% pullback of 2021 in early October, the S&P 500 has come roaring back and closed at a record high on October 21. The S&P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.\nThat could be a positive sign for investors in the coming months. The past seven times the S&P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.\n“We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":998,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840350426,"gmtCreate":1635594544896,"gmtModify":1635594544896,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840350426","repostId":"2179223688","repostType":4,"isVote":1,"tweetType":1,"viewCount":1018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854417998,"gmtCreate":1635473334372,"gmtModify":1635473341396,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Fellow closely","listText":"Fellow closely","text":"Fellow closely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854417998","repostId":"1146294800","repostType":4,"repost":{"id":"1146294800","kind":"news","pubTimestamp":1635472918,"share":"https://www.laohu8.com/m/news/1146294800?lang=zh_CN&edition=full","pubTime":"2021-10-29 10:01","market":"us","language":"en","title":"Apple and Amazon are struggling, so investors may want to look to these tech stocks instead<blockquote>苹果和亚马逊正在苦苦挣扎，因此投资者可能会转而关注这些科技股</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1146294800","media":"MarketWatch","summary":"As companies focused on getting goods to consumers struggle with supply-chain issues heading into th","content":"<p>As companies focused on getting goods to consumers struggle with supply-chain issues heading into the holidays, enterprise software companies are looking strong</p><p><blockquote>随着专注于向消费者提供商品的公司在假期前努力解决供应链问题，企业软件公司看起来表现强劲</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b0123d1db0a69d3c06a49bc51bc84fc1\" tg-width=\"700\" tg-height=\"464\" referrerpolicy=\"no-referrer\"><span>A logjam of container ships, at top, wait to offload at the Port of Los Angeles in September. Supply-chain issues are expected to weigh heavily on both Apple and Amazon this quarter.</span></p><p><blockquote><p class=\"t-img-caption\"><span>九月，一艘集装箱船在洛杉矶港等待卸货。供应链问题预计将在本季度给苹果和亚马逊带来沉重压力。</span></p></blockquote></p><p> Both Apple Inc. and Amazon.com Inc. had rare earnings disappointments on Thursday, which may lead investors to look in another direction for big holiday returns.</p><p><blockquote>苹果公司和亚马逊公司周四的盈利都罕见地令人失望，这可能会导致投资者转向另一个方向寻求丰厚的假期回报。</blockquote></p><p> This column warned that the two tech giants could stumble this quarter, as the supply-chain issues that had been affecting other industries took a bite out of both Apple&nbsp;and Amazon.It appears those issues will continue into the normally huge holiday quarter for the consumer-focused companies, while a natural rival of both — Microsoft Corp.&nbsp;— offered a huge holiday forecast just a few days earlier.</p><p><blockquote>本专栏警告称，这两家科技巨头本季度可能会陷入困境，因为一直影响其他行业的供应链问题对苹果和亚马逊都造成了影响。对于以消费者为中心的公司来说，这些问题似乎将持续到通常巨大的假期季度，而两者的天然竞争对手——微软公司——就在几天前提供了巨大的假期预测。</blockquote></p><p> Apple reported a rare revenue miss — its first since the December quarter of 2018 — with revenue of $83.4 billion coming in $1.7 billion below analysts’ estimates of $85.1 billion for its fiscal fourth quarter. Since the pandemic, Apple no longer gives revenue guidance, but the bulk of the revenue shortfall came from iPhone sales, which came in $2.1 billion below analysts expectations. Sales of Macs and iPads, however, exceeded estimates.</p><p><blockquote>苹果公布了罕见的营收下滑，这是自2018年12月季度以来的首次下滑，第四财季营收为834亿美元，比分析师预期的851亿美元低17亿美元。自疫情爆发以来，苹果不再给出收入指引，但大部分收入缺口来自iPhone销量，比分析师预期低21亿美元。然而，Mac和iPad的销量超出了预期。</blockquote></p><p> Apple’s Chief Financial Officer Luca Maestri told analysts that the ongoing supply constraints hurt its revenue by around $6 billion, and that the impact will be larger in the December quarter. The products most effected were the iPhone, the iPad and the Mac, and the constraints were caused by both semiconductor shortages and manufacturing disruptions because of the COVID-19 pandemic.</p><p><blockquote>苹果首席财务官Luca Maestri告诉分析师，持续的供应限制使其收入损失了约60亿美元，并且在12月季度的影响将更大。受影响最大的产品是iPhone、iPad和Mac，这些限制是由半导体短缺和COVID-19大流行导致的制造中断造成的。</blockquote></p><p> Amazon reported an even sharper-than-expected drop in earnings, with a huge surge in expenses, as it tried to shore up staff and dealt with unprecedented supply-chain issues. Amazon’s costs to fulfill and ship orders increased to $18.5 billion from $14.71 billion. Amazon reported third-quarter earnings per share of $6.12, a drop of nearly 50% from the year-ago and below analysts’ average expectations of $8.90 a share.</p><p><blockquote>亚马逊报告称，由于试图支持员工并处理前所未有的供应链问题，盈利下降幅度甚至超出预期，支出大幅飙升。亚马逊履行和运送订单的成本从147.1亿美元增加到185亿美元。亚马逊公布第三季度每股收益为6.12美元，同比下降近50%，低于分析师平均预期的每股8.90美元。</blockquote></p><p> These higher fulfillment and employee costs, like Apple’s supply-chain constraints, will continue in the fourth quarter, usually the biggest for consumer-related tech companies. Amazon CEO Andy Jassy said in a statement that Amazon expects to incur “several billion dollars of additional costs” in its consumer business, as it deals with “labor supply shortages, increased wage costs, global supply-chain issues, and increased freight and shipping costs.”</p><p><blockquote>这些较高的履行和员工成本，例如苹果的供应链限制，将在第四季度持续下去，这通常是消费者相关科技公司最大的。亚马逊首席执行官安迪·贾西在一份声明中表示，亚马逊预计其消费者业务将产生“数十亿美元的额外成本”，因为该公司要应对“劳动力供应短缺、工资成本增加、全球供应链问题以及运费和运输成本增加”。”</blockquote></p><p> The shares of both tech mega stars — which both trade over $1 trillion in market cap — tumbled in after-hours trading, with Apple falling 3.53% while Amazon lost 4%.</p><p><blockquote>这两家市值均超过1万亿美元的科技巨头的股价在盘后交易中暴跌，其中苹果下跌3.53%，亚马逊下跌4%。</blockquote></p><p> While neither company is seeing any loss of demand — in fact the opposite is occurring because they cannot keep up with demand amid the global shipping and product constraints — the news was a downer for investors counting on them to finish the year strongly. As consumer-focused companies could have a harder time meeting all the demand in the upcoming holiday season, corporate-focused tech giants — such as Microsoft — could be a safer play for now.</p><p><blockquote>虽然两家公司都没有看到任何需求损失——事实上，情况恰恰相反，因为在全球运输和产品限制的情况下，它们无法跟上需求——但这一消息令指望它们强劲结束今年的投资者感到沮丧。由于以消费者为中心的公司可能很难在即将到来的假期满足所有需求，因此以企业为中心的科技巨头——例如微软——目前可能是更安全的选择。</blockquote></p><p> Earlier this week, Microsoft topped $20 billion in net income for the first time, with PC revenue beating expectations and the company’s fast-growing cloud business still its biggest driver. The company’s shares were up slightly in after-hours trading Thursday and were on the way to potentially surpassing Apple in market value in regular trading hours on Friday.</p><p><blockquote>本周早些时候，微软净利润首次突破200亿美元，PC收入超出预期，该公司快速增长的云业务仍是其最大驱动力。该公司股价在周四盘后交易中小幅上涨，并有望在周五常规交易时间超过苹果。</blockquote></p><p> Microsoft is not the only software name trending higher heading into the holidays. Atlassian,the maker of team collaboration software, saw its shares soar 9% on Thursday after blowing past Wall Street’s estimates&nbsp;and seeing revenue for its its cloud-based products soar 50%. On Wednesday, cloud-based software provider ServiceNow Inc.&nbsp;beat estimates, and one analyst on Wall Street raised its price target; its shares climbed 3.45% on Thursday.</p><p><blockquote>微软并不是唯一一个在假期期间走高的软件公司。团队协作软件制造商Atlassian周四股价飙升9%，此前其基于云的产品收入飙升50%，超出了华尔街的预期。周三，基于云的软件提供商ServiceNow Inc.超出预期，华尔街一位分析师上调了其目标价；周四其股价上涨3.45%。</blockquote></p><p> Investors looking to stock up on tech stocks for the holidays might want to move away from the traditional players — like Apple and Amazon — and look at enterprise software developers and other cloud-computing players. They may be a bit more boring, but they are poised for more growth in the coming fourth quarter, and could be better stocking-stuffers than the more consumer-focused giants.</p><p><blockquote>希望在假期买入科技股的投资者可能希望远离苹果和亚马逊等传统公司，转而关注企业软件开发商和其他云计算公司。它们可能有点无聊，但它们有望在即将到来的第四季度实现更多增长，并且可能比更注重消费者的巨头更好地填充库存。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple and Amazon are struggling, so investors may want to look to these tech stocks instead<blockquote>苹果和亚马逊正在苦苦挣扎，因此投资者可能会转而关注这些科技股</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple and Amazon are struggling, so investors may want to look to these tech stocks instead<blockquote>苹果和亚马逊正在苦苦挣扎，因此投资者可能会转而关注这些科技股</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-10-29 10:01</span>\n</p>\n</h4>\n</header>\n<article>\n<p>As companies focused on getting goods to consumers struggle with supply-chain issues heading into the holidays, enterprise software companies are looking strong</p><p><blockquote>随着专注于向消费者提供商品的公司在假期前努力解决供应链问题，企业软件公司看起来表现强劲</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b0123d1db0a69d3c06a49bc51bc84fc1\" tg-width=\"700\" tg-height=\"464\" referrerpolicy=\"no-referrer\"><span>A logjam of container ships, at top, wait to offload at the Port of Los Angeles in September. Supply-chain issues are expected to weigh heavily on both Apple and Amazon this quarter.</span></p><p><blockquote><p class=\"t-img-caption\"><span>九月，一艘集装箱船在洛杉矶港等待卸货。供应链问题预计将在本季度给苹果和亚马逊带来沉重压力。</span></p></blockquote></p><p> Both Apple Inc. and Amazon.com Inc. had rare earnings disappointments on Thursday, which may lead investors to look in another direction for big holiday returns.</p><p><blockquote>苹果公司和亚马逊公司周四的盈利都罕见地令人失望，这可能会导致投资者转向另一个方向寻求丰厚的假期回报。</blockquote></p><p> This column warned that the two tech giants could stumble this quarter, as the supply-chain issues that had been affecting other industries took a bite out of both Apple&nbsp;and Amazon.It appears those issues will continue into the normally huge holiday quarter for the consumer-focused companies, while a natural rival of both — Microsoft Corp.&nbsp;— offered a huge holiday forecast just a few days earlier.</p><p><blockquote>本专栏警告称，这两家科技巨头本季度可能会陷入困境，因为一直影响其他行业的供应链问题对苹果和亚马逊都造成了影响。对于以消费者为中心的公司来说，这些问题似乎将持续到通常巨大的假期季度，而两者的天然竞争对手——微软公司——就在几天前提供了巨大的假期预测。</blockquote></p><p> Apple reported a rare revenue miss — its first since the December quarter of 2018 — with revenue of $83.4 billion coming in $1.7 billion below analysts’ estimates of $85.1 billion for its fiscal fourth quarter. Since the pandemic, Apple no longer gives revenue guidance, but the bulk of the revenue shortfall came from iPhone sales, which came in $2.1 billion below analysts expectations. Sales of Macs and iPads, however, exceeded estimates.</p><p><blockquote>苹果公布了罕见的营收下滑，这是自2018年12月季度以来的首次下滑，第四财季营收为834亿美元，比分析师预期的851亿美元低17亿美元。自疫情爆发以来，苹果不再给出收入指引，但大部分收入缺口来自iPhone销量，比分析师预期低21亿美元。然而，Mac和iPad的销量超出了预期。</blockquote></p><p> Apple’s Chief Financial Officer Luca Maestri told analysts that the ongoing supply constraints hurt its revenue by around $6 billion, and that the impact will be larger in the December quarter. The products most effected were the iPhone, the iPad and the Mac, and the constraints were caused by both semiconductor shortages and manufacturing disruptions because of the COVID-19 pandemic.</p><p><blockquote>苹果首席财务官Luca Maestri告诉分析师，持续的供应限制使其收入损失了约60亿美元，并且在12月季度的影响将更大。受影响最大的产品是iPhone、iPad和Mac，这些限制是由半导体短缺和COVID-19大流行导致的制造中断造成的。</blockquote></p><p> Amazon reported an even sharper-than-expected drop in earnings, with a huge surge in expenses, as it tried to shore up staff and dealt with unprecedented supply-chain issues. Amazon’s costs to fulfill and ship orders increased to $18.5 billion from $14.71 billion. Amazon reported third-quarter earnings per share of $6.12, a drop of nearly 50% from the year-ago and below analysts’ average expectations of $8.90 a share.</p><p><blockquote>亚马逊报告称，由于试图支持员工并处理前所未有的供应链问题，盈利下降幅度甚至超出预期，支出大幅飙升。亚马逊履行和运送订单的成本从147.1亿美元增加到185亿美元。亚马逊公布第三季度每股收益为6.12美元，同比下降近50%，低于分析师平均预期的每股8.90美元。</blockquote></p><p> These higher fulfillment and employee costs, like Apple’s supply-chain constraints, will continue in the fourth quarter, usually the biggest for consumer-related tech companies. Amazon CEO Andy Jassy said in a statement that Amazon expects to incur “several billion dollars of additional costs” in its consumer business, as it deals with “labor supply shortages, increased wage costs, global supply-chain issues, and increased freight and shipping costs.”</p><p><blockquote>这些较高的履行和员工成本，例如苹果的供应链限制，将在第四季度持续下去，这通常是消费者相关科技公司最大的。亚马逊首席执行官安迪·贾西在一份声明中表示，亚马逊预计其消费者业务将产生“数十亿美元的额外成本”，因为该公司要应对“劳动力供应短缺、工资成本增加、全球供应链问题以及运费和运输成本增加”。”</blockquote></p><p> The shares of both tech mega stars — which both trade over $1 trillion in market cap — tumbled in after-hours trading, with Apple falling 3.53% while Amazon lost 4%.</p><p><blockquote>这两家市值均超过1万亿美元的科技巨头的股价在盘后交易中暴跌，其中苹果下跌3.53%，亚马逊下跌4%。</blockquote></p><p> While neither company is seeing any loss of demand — in fact the opposite is occurring because they cannot keep up with demand amid the global shipping and product constraints — the news was a downer for investors counting on them to finish the year strongly. As consumer-focused companies could have a harder time meeting all the demand in the upcoming holiday season, corporate-focused tech giants — such as Microsoft — could be a safer play for now.</p><p><blockquote>虽然两家公司都没有看到任何需求损失——事实上，情况恰恰相反，因为在全球运输和产品限制的情况下，它们无法跟上需求——但这一消息令指望它们强劲结束今年的投资者感到沮丧。由于以消费者为中心的公司可能很难在即将到来的假期满足所有需求，因此以企业为中心的科技巨头——例如微软——目前可能是更安全的选择。</blockquote></p><p> Earlier this week, Microsoft topped $20 billion in net income for the first time, with PC revenue beating expectations and the company’s fast-growing cloud business still its biggest driver. The company’s shares were up slightly in after-hours trading Thursday and were on the way to potentially surpassing Apple in market value in regular trading hours on Friday.</p><p><blockquote>本周早些时候，微软净利润首次突破200亿美元，PC收入超出预期，该公司快速增长的云业务仍是其最大驱动力。该公司股价在周四盘后交易中小幅上涨，并有望在周五常规交易时间超过苹果。</blockquote></p><p> Microsoft is not the only software name trending higher heading into the holidays. Atlassian,the maker of team collaboration software, saw its shares soar 9% on Thursday after blowing past Wall Street’s estimates&nbsp;and seeing revenue for its its cloud-based products soar 50%. On Wednesday, cloud-based software provider ServiceNow Inc.&nbsp;beat estimates, and one analyst on Wall Street raised its price target; its shares climbed 3.45% on Thursday.</p><p><blockquote>微软并不是唯一一个在假期期间走高的软件公司。团队协作软件制造商Atlassian周四股价飙升9%，此前其基于云的产品收入飙升50%，超出了华尔街的预期。周三，基于云的软件提供商ServiceNow Inc.超出预期，华尔街一位分析师上调了其目标价；周四其股价上涨3.45%。</blockquote></p><p> Investors looking to stock up on tech stocks for the holidays might want to move away from the traditional players — like Apple and Amazon — and look at enterprise software developers and other cloud-computing players. They may be a bit more boring, but they are poised for more growth in the coming fourth quarter, and could be better stocking-stuffers than the more consumer-focused giants.</p><p><blockquote>希望在假期买入科技股的投资者可能希望远离苹果和亚马逊等传统公司，转而关注企业软件开发商和其他云计算公司。它们可能有点无聊，但它们有望在即将到来的第四季度实现更多增长，并且可能比更注重消费者的巨头更好地填充库存。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/apple-and-amazon-are-struggling-so-investors-may-want-to-look-to-these-tech-stocks-instead-11635469850?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","NOW":"ServiceNow","TEAM":"Atlassian Corporation PLC","MSFT":"微软","AAPL":"苹果"},"source_url":"https://www.marketwatch.com/story/apple-and-amazon-are-struggling-so-investors-may-want-to-look-to-these-tech-stocks-instead-11635469850?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146294800","content_text":"As companies focused on getting goods to consumers struggle with supply-chain issues heading into the holidays, enterprise software companies are looking strong\nA logjam of container ships, at top, wait to offload at the Port of Los Angeles in September. Supply-chain issues are expected to weigh heavily on both Apple and Amazon this quarter.\nBoth Apple Inc. and Amazon.com Inc. had rare earnings disappointments on Thursday, which may lead investors to look in another direction for big holiday returns.\nThis column warned that the two tech giants could stumble this quarter, as the supply-chain issues that had been affecting other industries took a bite out of both Apple and Amazon.It appears those issues will continue into the normally huge holiday quarter for the consumer-focused companies, while a natural rival of both — Microsoft Corp. — offered a huge holiday forecast just a few days earlier.\nApple reported a rare revenue miss — its first since the December quarter of 2018 — with revenue of $83.4 billion coming in $1.7 billion below analysts’ estimates of $85.1 billion for its fiscal fourth quarter. Since the pandemic, Apple no longer gives revenue guidance, but the bulk of the revenue shortfall came from iPhone sales, which came in $2.1 billion below analysts expectations. Sales of Macs and iPads, however, exceeded estimates.\nApple’s Chief Financial Officer Luca Maestri told analysts that the ongoing supply constraints hurt its revenue by around $6 billion, and that the impact will be larger in the December quarter. The products most effected were the iPhone, the iPad and the Mac, and the constraints were caused by both semiconductor shortages and manufacturing disruptions because of the COVID-19 pandemic.\nAmazon reported an even sharper-than-expected drop in earnings, with a huge surge in expenses, as it tried to shore up staff and dealt with unprecedented supply-chain issues. Amazon’s costs to fulfill and ship orders increased to $18.5 billion from $14.71 billion. Amazon reported third-quarter earnings per share of $6.12, a drop of nearly 50% from the year-ago and below analysts’ average expectations of $8.90 a share.\nThese higher fulfillment and employee costs, like Apple’s supply-chain constraints, will continue in the fourth quarter, usually the biggest for consumer-related tech companies. Amazon CEO Andy Jassy said in a statement that Amazon expects to incur “several billion dollars of additional costs” in its consumer business, as it deals with “labor supply shortages, increased wage costs, global supply-chain issues, and increased freight and shipping costs.”\nThe shares of both tech mega stars — which both trade over $1 trillion in market cap — tumbled in after-hours trading, with Apple falling 3.53% while Amazon lost 4%.\nWhile neither company is seeing any loss of demand — in fact the opposite is occurring because they cannot keep up with demand amid the global shipping and product constraints — the news was a downer for investors counting on them to finish the year strongly. As consumer-focused companies could have a harder time meeting all the demand in the upcoming holiday season, corporate-focused tech giants — such as Microsoft — could be a safer play for now.\nEarlier this week, Microsoft topped $20 billion in net income for the first time, with PC revenue beating expectations and the company’s fast-growing cloud business still its biggest driver. The company’s shares were up slightly in after-hours trading Thursday and were on the way to potentially surpassing Apple in market value in regular trading hours on Friday.\nMicrosoft is not the only software name trending higher heading into the holidays. Atlassian,the maker of team collaboration software, saw its shares soar 9% on Thursday after blowing past Wall Street’s estimates and seeing revenue for its its cloud-based products soar 50%. On Wednesday, cloud-based software provider ServiceNow Inc. beat estimates, and one analyst on Wall Street raised its price target; its shares climbed 3.45% on Thursday.\nInvestors looking to stock up on tech stocks for the holidays might want to move away from the traditional players — like Apple and Amazon — and look at enterprise software developers and other cloud-computing players. They may be a bit more boring, but they are poised for more growth in the coming fourth quarter, and could be better stocking-stuffers than the more consumer-focused giants.","news_type":1,"symbols_score_info":{"NOW":0.9,"TEAM":0.9,"MSFT":0.9,"AMZN":0.9,"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858779922,"gmtCreate":1635126069049,"gmtModify":1635126708192,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Watch closely","listText":"Watch closely","text":"Watch closely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858779922","repostId":"2178808449","repostType":4,"isVote":1,"tweetType":1,"viewCount":1389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828211346,"gmtCreate":1633915801164,"gmtModify":1633915801211,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828211346","repostId":"1130055962","repostType":2,"repost":{"id":"1130055962","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633907445,"share":"https://www.laohu8.com/m/news/1130055962?lang=zh_CN&edition=full","pubTime":"2021-10-11 07:10","market":"sh","language":"zh","title":"前瞻：美股财报季开启！美联储将公布会议纪要","url":"https://stock-news.laohu8.com/highlight/detail?id=1130055962","media":"老虎资讯综合","summary":"摘要：\n\n 数据方面：又迎“超级周”！市场迎来中国CPI、PPI数据和进出口数据，美国将公布CPI、PPI、零售销售等数据\n\n\n 财报方面：财报季拉开序幕，大型银行股打头阵！美国银行、富国银行、花旗、","content":"<p>摘要：</p>\n<blockquote>\n 数据方面：又迎“超级周”！市场迎来中国CPI、PPI数据和进出口数据，美国将公布CPI、PPI、零售销售等数据\n</blockquote>\n<blockquote>\n 财报方面：财报季拉开序幕，大型银行股打头阵！美国银行、富国银行、花旗、大摩、高盛业绩来袭，半导体巨头台积电财报值得期待\n</blockquote>\n<blockquote>\n 事件方面：美国众议院对临时提高债务上限法案进行投票表决；美联储将公布会议纪要\n</blockquote>\n<blockquote>\n 周四重阳节，港股休市一日\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/aa0421b55f719ef0912164a72dcd463a\" tg-width=\"1878\" tg-height=\"2943\" width=\"100%\" height=\"auto\"><b>周一（10月11日）关键词：9月用电量数据、美股新股IPO</b><img src=\"https://static.tigerbbs.com/db75184f624b22b76c2e9c71f6b65b14\" tg-width=\"715\" tg-height=\"550\" referrerpolicy=\"no-referrer\">周一重磅事件较少，主要留意周末消息对行情的影响。国内方面，投资者需要予以留意<b>中国全社会用电量数据。</b></p>\n<p><b>新股方面，</b>美股医疗保健文档软件提供商<b><a href=\"https://laohu8.com/S/AUGX\">Augmedix</a></b>以及生物制药公司<b><a href=\"https://laohu8.com/S/CING\">Cingulate</a></b>上市。</p>\n<p><b>周二（10月12日）关键词：美国临时提高债务上限法案投票</b><img src=\"https://static.tigerbbs.com/efb6bf42c21fca28b0d6803e26444b67\" tg-width=\"624\" tg-height=\"279\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/29479a44ca9cccfd161928ee27aadc6d\" tg-width=\"917\" tg-height=\"462\" referrerpolicy=\"no-referrer\">事件方面，投资者需要关注<b>美国众议院对临时提高债务上限法案进行投票表决。</b></p>\n<p>10月8日&nbsp;美国参议院以50票对48票通过提高债务上限法案，众议院将于10月12日对临时提高债务上限法案进行投票表决，目前来看，通过的可能性较大，美国总统拜登将在众议院通过临时债务上限法案后签署该法案。</p>\n<p><b>财报方面，</b>工业和建筑用品批发分销公司<b><a href=\"https://laohu8.com/S/FAST\">快扣</a></b>将于美股盘前公布财报。</p>\n<p><b>周三（10月13日）关键词：中国9月贸易帐、美国9月CPI、摩根大通/贝莱德/达美航空财报、和誉-B上市</b><img src=\"https://static.tigerbbs.com/4203e99d5f8babde8c7488ea60f40b64\" tg-width=\"633\" tg-height=\"707\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/06d111ff8cf0bf8596ad61fee12619c0\" tg-width=\"929\" tg-height=\"388\" referrerpolicy=\"no-referrer\"><b>经济数据方面，</b>首先关注<b>中国9月份的贸易数据</b>。分析师预计，中国9月进出口增速可能较8月放缓，但仍可能保持健康增长。</p>\n<p>此外，<b>美国9月份的CPI数据，</b>也是市场关注的焦点。分析师预计美国9月份CPI同比小幅上升至5.4％，略高于5.3％的普遍预期。由于自然灾害和新冠肺炎在美国和亚洲的蔓延，中断供应链瓶颈的再度加剧在9月份对制成品构成了压力。</p>\n<p><b>财报方面，</b>美国企业新一轮财报季拉开序幕。<b><a href=\"https://laohu8.com/S/JPM\">摩根大通</a>、<a href=\"https://laohu8.com/S/DAL\">达美航空</a>、<a href=\"https://laohu8.com/S/BLK\">贝莱德</a></b>等将于周三美股盘前公布财报。</p>\n<blockquote>\n 在企业盈利连续几个季度创下纪录后，投资者正在评估盈利增长能否继续引领股市走高。高盛提醒称，供应链限制、油价上涨以及劳动力成本增加均是即将到来的财报季需要关注的主要风险。\n</blockquote>\n<p><b>新股方面，</b>港股<b><a href=\"https://laohu8.com/S/02256\">和誉-B</a></b>、美股自动化支付解决方案提供商<b><a href=\"https://laohu8.com/S/AVDX\">AvidXchange Holdings, Inc.</a></b>将于本日上市。</p>\n<p><b>周四（10月14日）关键词：中国9月CPI和PPI、美国9月PPI数据、美大型银行股财报、台积电财报</b><img src=\"https://static.tigerbbs.com/09bbedc20f13eb154932de4c4da559ec\" tg-width=\"627\" tg-height=\"684\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/6e6d99af47432bc4b5f9aaf484e637bb\" tg-width=\"917\" tg-height=\"449\" referrerpolicy=\"no-referrer\">数据方面，<b>国家统计局将公布9月CPI、PPI数据。</b></p>\n<p>对于PPI的后续走势，统计局新闻发言人付凌晖分析，短期内PPI可能还会高位运行，未来走势总的看还需要观察。一方面，国际大宗商品价格目前仍然保持高位，虽然近期涨幅有所回落，但还存在一定不确定性。</p>\n<p>其次，投资者需要重点关注<b>美国每周的初请失业金人数变动和9月PPI数据。</b></p>\n<blockquote>\n 分析师预计，初值首次申领失业救济人数将继续下滑，因为delta变种病例的激增已经消退，经济活动回升。预计首次申请失业救济人数将减少2.6万人，10月初为减少3.8万人，将完全扭转前三周总计5.2万人的暂时增长。\n</blockquote>\n<p><b>事件方面，</b>10月14日为重阳节，<b>港股市场休市一日。</b></p>\n<p>其次，投资者需要重点关注<b>美联储会议纪要</b>，9月份的利率决议偏向鹰派，基本敲定了11月份缩减购债规模的时间安排，但会议纪要鹰派不及预期的可能性比较大。</p>\n<p><b>财报方面，</b>大型银行股扎堆公布财报。据金融博客ZeroHedge，美国大型银行将从10月11日当周开始发布业绩报告，占标普500市值47%的公司将在10月25日当周发布，86%将在11月6日前发布，敬请留意。</p>\n<p>打头阵的银行股将最受关注，周四盘前，<b><a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、<a href=\"https://laohu8.com/S/USB\">美国合众银行</a>、<a href=\"https://laohu8.com/S/BAC\">美国银行</a>、<a href=\"https://laohu8.com/S/WFC\">富国银行</a>、<a href=\"https://laohu8.com/S/C\">花旗集团</a></b>等相继公布业绩报告，将有助于市场了解美国经济的强劲程度、贷款需求，甚至消费者支出。（金融部门的利润预计将增长18%。）</p>\n<p>此外，<b><a href=\"https://laohu8.com/S/TSM\">台积电</a></b>也将于盘前公布财报。</p>\n<p>新股方面，重点关注代码托管平台<b><a href=\"https://laohu8.com/S/GTLB\">Gitlab</a></b>上市。</p>\n<p><b>周五（10月15日）关键词：美国9月恐怖数据、高盛财报</b><img src=\"https://static.tigerbbs.com/fa62e19b6611d86ef0d55e03e3ab96b7\" tg-width=\"626\" tg-height=\"319\" referrerpolicy=\"no-referrer\">周五，主要关注纽约时段的<b>美国9月零售销售数据，</b>该数据因为对行情的影响较大，市场关注度较高，有着「恐怖数据」的俗称，投资者需要重点关注。</p>\n<blockquote>\n 分析师估计9月份零售支出温和下降，将反映出各个行业的不均衡表现，这是自3月份刺激措施激增以来的主题。从通胀调整后的角度来看，降幅将更大，这进一步证明消费者支出将难以实现定于10月晚些时候发布的第三季度GDP数据的增长。\n</blockquote>\n<p>财报方面，港股<b><a href=\"https://laohu8.com/S/02899\">紫金矿业</a></b>、美股<b><a href=\"https://laohu8.com/S/GS\">高盛</a></b>分别于此日公布业绩。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>前瞻：美股财报季开启！美联储将公布会议纪要</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n前瞻：美股财报季开启！美联储将公布会议纪要\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-10-11 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>摘要：</p>\n<blockquote>\n 数据方面：又迎“超级周”！市场迎来中国CPI、PPI数据和进出口数据，美国将公布CPI、PPI、零售销售等数据\n</blockquote>\n<blockquote>\n 财报方面：财报季拉开序幕，大型银行股打头阵！美国银行、富国银行、花旗、大摩、高盛业绩来袭，半导体巨头台积电财报值得期待\n</blockquote>\n<blockquote>\n 事件方面：美国众议院对临时提高债务上限法案进行投票表决；美联储将公布会议纪要\n</blockquote>\n<blockquote>\n 周四重阳节，港股休市一日\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/aa0421b55f719ef0912164a72dcd463a\" tg-width=\"1878\" tg-height=\"2943\" width=\"100%\" height=\"auto\"><b>周一（10月11日）关键词：9月用电量数据、美股新股IPO</b><img src=\"https://static.tigerbbs.com/db75184f624b22b76c2e9c71f6b65b14\" tg-width=\"715\" tg-height=\"550\" referrerpolicy=\"no-referrer\">周一重磅事件较少，主要留意周末消息对行情的影响。国内方面，投资者需要予以留意<b>中国全社会用电量数据。</b></p>\n<p><b>新股方面，</b>美股医疗保健文档软件提供商<b><a href=\"https://laohu8.com/S/AUGX\">Augmedix</a></b>以及生物制药公司<b><a href=\"https://laohu8.com/S/CING\">Cingulate</a></b>上市。</p>\n<p><b>周二（10月12日）关键词：美国临时提高债务上限法案投票</b><img src=\"https://static.tigerbbs.com/efb6bf42c21fca28b0d6803e26444b67\" tg-width=\"624\" tg-height=\"279\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/29479a44ca9cccfd161928ee27aadc6d\" tg-width=\"917\" tg-height=\"462\" referrerpolicy=\"no-referrer\">事件方面，投资者需要关注<b>美国众议院对临时提高债务上限法案进行投票表决。</b></p>\n<p>10月8日&nbsp;美国参议院以50票对48票通过提高债务上限法案，众议院将于10月12日对临时提高债务上限法案进行投票表决，目前来看，通过的可能性较大，美国总统拜登将在众议院通过临时债务上限法案后签署该法案。</p>\n<p><b>财报方面，</b>工业和建筑用品批发分销公司<b><a href=\"https://laohu8.com/S/FAST\">快扣</a></b>将于美股盘前公布财报。</p>\n<p><b>周三（10月13日）关键词：中国9月贸易帐、美国9月CPI、摩根大通/贝莱德/达美航空财报、和誉-B上市</b><img src=\"https://static.tigerbbs.com/4203e99d5f8babde8c7488ea60f40b64\" tg-width=\"633\" tg-height=\"707\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/06d111ff8cf0bf8596ad61fee12619c0\" tg-width=\"929\" tg-height=\"388\" referrerpolicy=\"no-referrer\"><b>经济数据方面，</b>首先关注<b>中国9月份的贸易数据</b>。分析师预计，中国9月进出口增速可能较8月放缓，但仍可能保持健康增长。</p>\n<p>此外，<b>美国9月份的CPI数据，</b>也是市场关注的焦点。分析师预计美国9月份CPI同比小幅上升至5.4％，略高于5.3％的普遍预期。由于自然灾害和新冠肺炎在美国和亚洲的蔓延，中断供应链瓶颈的再度加剧在9月份对制成品构成了压力。</p>\n<p><b>财报方面，</b>美国企业新一轮财报季拉开序幕。<b><a href=\"https://laohu8.com/S/JPM\">摩根大通</a>、<a href=\"https://laohu8.com/S/DAL\">达美航空</a>、<a href=\"https://laohu8.com/S/BLK\">贝莱德</a></b>等将于周三美股盘前公布财报。</p>\n<blockquote>\n 在企业盈利连续几个季度创下纪录后，投资者正在评估盈利增长能否继续引领股市走高。高盛提醒称，供应链限制、油价上涨以及劳动力成本增加均是即将到来的财报季需要关注的主要风险。\n</blockquote>\n<p><b>新股方面，</b>港股<b><a href=\"https://laohu8.com/S/02256\">和誉-B</a></b>、美股自动化支付解决方案提供商<b><a href=\"https://laohu8.com/S/AVDX\">AvidXchange Holdings, Inc.</a></b>将于本日上市。</p>\n<p><b>周四（10月14日）关键词：中国9月CPI和PPI、美国9月PPI数据、美大型银行股财报、台积电财报</b><img src=\"https://static.tigerbbs.com/09bbedc20f13eb154932de4c4da559ec\" tg-width=\"627\" tg-height=\"684\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/6e6d99af47432bc4b5f9aaf484e637bb\" tg-width=\"917\" tg-height=\"449\" referrerpolicy=\"no-referrer\">数据方面，<b>国家统计局将公布9月CPI、PPI数据。</b></p>\n<p>对于PPI的后续走势，统计局新闻发言人付凌晖分析，短期内PPI可能还会高位运行，未来走势总的看还需要观察。一方面，国际大宗商品价格目前仍然保持高位，虽然近期涨幅有所回落，但还存在一定不确定性。</p>\n<p>其次，投资者需要重点关注<b>美国每周的初请失业金人数变动和9月PPI数据。</b></p>\n<blockquote>\n 分析师预计，初值首次申领失业救济人数将继续下滑，因为delta变种病例的激增已经消退，经济活动回升。预计首次申请失业救济人数将减少2.6万人，10月初为减少3.8万人，将完全扭转前三周总计5.2万人的暂时增长。\n</blockquote>\n<p><b>事件方面，</b>10月14日为重阳节，<b>港股市场休市一日。</b></p>\n<p>其次，投资者需要重点关注<b>美联储会议纪要</b>，9月份的利率决议偏向鹰派，基本敲定了11月份缩减购债规模的时间安排，但会议纪要鹰派不及预期的可能性比较大。</p>\n<p><b>财报方面，</b>大型银行股扎堆公布财报。据金融博客ZeroHedge，美国大型银行将从10月11日当周开始发布业绩报告，占标普500市值47%的公司将在10月25日当周发布，86%将在11月6日前发布，敬请留意。</p>\n<p>打头阵的银行股将最受关注，周四盘前，<b><a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、<a href=\"https://laohu8.com/S/USB\">美国合众银行</a>、<a href=\"https://laohu8.com/S/BAC\">美国银行</a>、<a href=\"https://laohu8.com/S/WFC\">富国银行</a>、<a href=\"https://laohu8.com/S/C\">花旗集团</a></b>等相继公布业绩报告，将有助于市场了解美国经济的强劲程度、贷款需求，甚至消费者支出。（金融部门的利润预计将增长18%。）</p>\n<p>此外，<b><a href=\"https://laohu8.com/S/TSM\">台积电</a></b>也将于盘前公布财报。</p>\n<p>新股方面，重点关注代码托管平台<b><a href=\"https://laohu8.com/S/GTLB\">Gitlab</a></b>上市。</p>\n<p><b>周五（10月15日）关键词：美国9月恐怖数据、高盛财报</b><img src=\"https://static.tigerbbs.com/fa62e19b6611d86ef0d55e03e3ab96b7\" tg-width=\"626\" tg-height=\"319\" referrerpolicy=\"no-referrer\">周五，主要关注纽约时段的<b>美国9月零售销售数据，</b>该数据因为对行情的影响较大，市场关注度较高，有着「恐怖数据」的俗称，投资者需要重点关注。</p>\n<blockquote>\n 分析师估计9月份零售支出温和下降，将反映出各个行业的不均衡表现，这是自3月份刺激措施激增以来的主题。从通胀调整后的角度来看，降幅将更大，这进一步证明消费者支出将难以实现定于10月晚些时候发布的第三季度GDP数据的增长。\n</blockquote>\n<p>财报方面，港股<b><a href=\"https://laohu8.com/S/02899\">紫金矿业</a></b>、美股<b><a href=\"https://laohu8.com/S/GS\">高盛</a></b>分别于此日公布业绩。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d256e82db1d71c864259845ce1d069bf","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130055962","content_text":"摘要：\n\n 数据方面：又迎“超级周”！市场迎来中国CPI、PPI数据和进出口数据，美国将公布CPI、PPI、零售销售等数据\n\n\n 财报方面：财报季拉开序幕，大型银行股打头阵！美国银行、富国银行、花旗、大摩、高盛业绩来袭，半导体巨头台积电财报值得期待\n\n\n 事件方面：美国众议院对临时提高债务上限法案进行投票表决；美联储将公布会议纪要\n\n\n 周四重阳节，港股休市一日\n\n周一（10月11日）关键词：9月用电量数据、美股新股IPO周一重磅事件较少，主要留意周末消息对行情的影响。国内方面，投资者需要予以留意中国全社会用电量数据。\n新股方面，美股医疗保健文档软件提供商Augmedix以及生物制药公司Cingulate上市。\n周二（10月12日）关键词：美国临时提高债务上限法案投票事件方面，投资者需要关注美国众议院对临时提高债务上限法案进行投票表决。\n10月8日 美国参议院以50票对48票通过提高债务上限法案，众议院将于10月12日对临时提高债务上限法案进行投票表决，目前来看，通过的可能性较大，美国总统拜登将在众议院通过临时债务上限法案后签署该法案。\n财报方面，工业和建筑用品批发分销公司快扣将于美股盘前公布财报。\n周三（10月13日）关键词：中国9月贸易帐、美国9月CPI、摩根大通/贝莱德/达美航空财报、和誉-B上市经济数据方面，首先关注中国9月份的贸易数据。分析师预计，中国9月进出口增速可能较8月放缓，但仍可能保持健康增长。\n此外，美国9月份的CPI数据，也是市场关注的焦点。分析师预计美国9月份CPI同比小幅上升至5.4％，略高于5.3％的普遍预期。由于自然灾害和新冠肺炎在美国和亚洲的蔓延，中断供应链瓶颈的再度加剧在9月份对制成品构成了压力。\n财报方面，美国企业新一轮财报季拉开序幕。摩根大通、达美航空、贝莱德等将于周三美股盘前公布财报。\n\n 在企业盈利连续几个季度创下纪录后，投资者正在评估盈利增长能否继续引领股市走高。高盛提醒称，供应链限制、油价上涨以及劳动力成本增加均是即将到来的财报季需要关注的主要风险。\n\n新股方面，港股和誉-B、美股自动化支付解决方案提供商AvidXchange Holdings, Inc.将于本日上市。\n周四（10月14日）关键词：中国9月CPI和PPI、美国9月PPI数据、美大型银行股财报、台积电财报数据方面，国家统计局将公布9月CPI、PPI数据。\n对于PPI的后续走势，统计局新闻发言人付凌晖分析，短期内PPI可能还会高位运行，未来走势总的看还需要观察。一方面，国际大宗商品价格目前仍然保持高位，虽然近期涨幅有所回落，但还存在一定不确定性。\n其次，投资者需要重点关注美国每周的初请失业金人数变动和9月PPI数据。\n\n 分析师预计，初值首次申领失业救济人数将继续下滑，因为delta变种病例的激增已经消退，经济活动回升。预计首次申请失业救济人数将减少2.6万人，10月初为减少3.8万人，将完全扭转前三周总计5.2万人的暂时增长。\n\n事件方面，10月14日为重阳节，港股市场休市一日。\n其次，投资者需要重点关注美联储会议纪要，9月份的利率决议偏向鹰派，基本敲定了11月份缩减购债规模的时间安排，但会议纪要鹰派不及预期的可能性比较大。\n财报方面，大型银行股扎堆公布财报。据金融博客ZeroHedge，美国大型银行将从10月11日当周开始发布业绩报告，占标普500市值47%的公司将在10月25日当周发布，86%将在11月6日前发布，敬请留意。\n打头阵的银行股将最受关注，周四盘前，摩根士丹利、美国合众银行、美国银行、富国银行、花旗集团等相继公布业绩报告，将有助于市场了解美国经济的强劲程度、贷款需求，甚至消费者支出。（金融部门的利润预计将增长18%。）\n此外，台积电也将于盘前公布财报。\n新股方面，重点关注代码托管平台Gitlab上市。\n周五（10月15日）关键词：美国9月恐怖数据、高盛财报周五，主要关注纽约时段的美国9月零售销售数据，该数据因为对行情的影响较大，市场关注度较高，有着「恐怖数据」的俗称，投资者需要重点关注。\n\n 分析师估计9月份零售支出温和下降，将反映出各个行业的不均衡表现，这是自3月份刺激措施激增以来的主题。从通胀调整后的角度来看，降幅将更大，这进一步证明消费者支出将难以实现定于10月晚些时候发布的第三季度GDP数据的增长。\n\n财报方面，港股紫金矿业、美股高盛分别于此日公布业绩。","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":1309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829175473,"gmtCreate":1633483720513,"gmtModify":1633483720657,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829175473","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829176459,"gmtCreate":1633483560669,"gmtModify":1633483597604,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Rise","listText":"Rise","text":"Rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829176459","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867672944,"gmtCreate":1633264701376,"gmtModify":1633264701459,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867672944","repostId":"2172643049","repostType":4,"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867678276,"gmtCreate":1633264383350,"gmtModify":1633264383493,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867678276","repostId":"2172614079","repostType":4,"isVote":1,"tweetType":1,"viewCount":998,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":874076607,"gmtCreate":1637716284407,"gmtModify":1637716284407,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Invest with precaution","listText":"Invest with precaution","text":"Invest with precaution","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/874076607","repostId":"1119695149","repostType":4,"isVote":1,"tweetType":1,"viewCount":3142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873057856,"gmtCreate":1636810156651,"gmtModify":1636810156651,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Pfizer continue to grow&nbsp;","listText":"Pfizer continue to grow&nbsp;","text":"Pfizer continue to grow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873057856","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840350426,"gmtCreate":1635594544896,"gmtModify":1635594544896,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840350426","repostId":"2179223688","repostType":4,"isVote":1,"tweetType":1,"viewCount":1018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829175473,"gmtCreate":1633483720513,"gmtModify":1633483720657,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829175473","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883669315,"gmtCreate":1631238254737,"gmtModify":1631885512082,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/883669315","repostId":"2166426123","repostType":4,"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869825822,"gmtCreate":1632273857566,"gmtModify":1632801578064,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"trade with caution","listText":"trade with caution","text":"trade with caution","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/869825822","repostId":"2169324976","repostType":4,"isVote":1,"tweetType":1,"viewCount":472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":849102179,"gmtCreate":1635732550275,"gmtModify":1635732550326,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Hope is a good month for stocks","listText":"Hope is a good month for stocks","text":"Hope is a good month for stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849102179","repostId":"1150912013","repostType":4,"repost":{"id":"1150912013","kind":"news","pubTimestamp":1635724788,"share":"https://www.laohu8.com/m/news/1150912013?lang=zh_CN&edition=full","pubTime":"2021-11-01 07:59","market":"us","language":"en","title":"What's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1150912013","media":"finance.yahoo","summary":"The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.“November is t","content":"<p>The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.</p><p><blockquote>如果历史有任何迹象的话，股市创纪录的走势将在未来几周内获得动力。</blockquote></p><p> The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.</p><p><blockquote>假期的开始通常是华尔街一年中的强劲时期，分析师指出，这种模式是保持乐观的理由，即股市在经历了动荡的9月份后将保持在历史高点。</blockquote></p><p> Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.</p><p><blockquote>根据LPL Financial的数据，从历史上看，11月一直是股市一年中表现最好的月份——无论是自1950年以来还是过去十年。</blockquote></p><p> That’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.</p><p><blockquote>这还不是全部。根据股票交易者年鉴，历史表明股市最强劲的六个月是11月至4月。11月也是市场最好的三个月（11月至1月）的第一个月。</blockquote></p><p> Why is November the best?</p><p><blockquote>为什么11月是最好的？</blockquote></p><p> This seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.</p><p><blockquote>这种季节性强势是由多种因素共同造成的。一方面，根据LPL Financial的数据，一年中的最后三个月通常是股市最好的月份，股市平均上涨3.8%。</blockquote></p><p> Strong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.</p><p><blockquote>购物者在假期期间的强劲支出也往往会转化为以消费者为中心的企业的强劲季度。一些分析师还将其归因于假期期间的乐观情绪、年终投资组合调整以及投资者正在度假。</blockquote></p><p> “November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”</p><p><blockquote>LPL Financial首席市场策略师瑞安·德特里克(Ryan Detrick)在给客户的一份报告中表示：“11月是一年中最好的月份，但它似乎并没有你想象的那么受欢迎。”“我们都认为12月是最好的月份，但11月实际上更好，而且很少大张旗鼓。也许这应该是多头的月份，而不是火鸡的月份。”</blockquote></p><p> Wall Street avoids spooky October</p><p><blockquote>华尔街避免幽灵般的十月</blockquote></p><p> While October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.</p><p><blockquote>虽然10月份对投资者来说通常被认为是一个幽灵般的月份，在1929年、1987年的崩盘和2008年全球金融危机期间赢得了坏名声，但今年投资者并没有那么害怕。</blockquote></p><p> After the S&amp;P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.</p><p><blockquote>在标普500 9月份录得自冠状病毒大流行开始以来的最大月度跌幅后，由于有进一步迹象表明企业利润在去年衰退后再次增长，该指数在10月份反弹了6%以上。</blockquote></p><p> “It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.</p><p><blockquote>《股票交易者年鉴》编辑杰夫·赫希(Jeff Hirsch)在给客户的一份报告中表示：“看起来市场已经抵制了‘十月恐惧症’，避免了令人恐惧的崩盘或大屠杀，这些崩盘或大屠杀给这个月带来了坏名声。”</blockquote></p><p> To be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.</p><p><blockquote>可以肯定的是，11月份在熊市期间遭受了打击，主要股指较近期峰值下跌了20%以上。</blockquote></p><p> For instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred</p><p><blockquote>例如，根据股票交易者年鉴，2000年11月是纳斯达克综合指数有记录以来第二糟糕的月份，以科技为重点的指数暴跌近23%。只有1987年10月更糟糕，那是“黑色星期一”股灾发生的时候</blockquote></p><p> Why investors should be optimistic</p><p><blockquote>为什么投资者应该乐观</blockquote></p><p> The U.S. economy&nbsp;slowed substantially from July through September&nbsp;following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.</p><p><blockquote>在经历了一系列障碍后，美国经济从7月到9月大幅放缓，包括COVID-19病例激增、供应链瓶颈、消费者价格上涨以及联邦刺激措施效果减弱。</blockquote></p><p> But with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.</p><p><blockquote>但随着新冠肺炎病例的下降和疫苗接种的增加，大多数经济学家认为，在从大流行引发的衰退中仍然强劲的复苏中，疲软表现出疲软，预计今年最后几个月将出现健康反弹。</blockquote></p><p> There are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.</p><p><blockquote>有迹象表明，由于强劲的季节性趋势、好于预期的企业盈利以及COVID-19病例下降，今年最后几个月华尔街可能会出现更多上涨。市场广度也有所改善，这意味着更多股票参与涨势，这是市场健康强劲的标志。</blockquote></p><p> Jobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.</p><p><blockquote>最近几周，申请失业救济人数也在稳步下降，最近申请失业救济人数自冠状病毒大流行开始以来首次降至250万以下。</blockquote></p><p> After suffering its first 5% pullback of 2021 in early October, the S&amp;P 500 has come roaring back and closed at a record high on October 21. The S&amp;P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.</p><p><blockquote>在10月初经历了2021年首次5%的回调后，标普500卷土重来，并于10月21日收于历史新高。标普500指数今年迄今已上涨超过20%，一路上创下50多个历史新高。</blockquote></p><p> That could be a positive sign for investors in the coming months. The past seven times the S&amp;P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.</p><p><blockquote>这对未来几个月的投资者来说可能是一个积极的信号。LPL Financial的数据显示，过去七次标普500在第四季度之前上涨了15%，最后一个季度每次都上涨了5.8%。</blockquote></p><p> “We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.</p><p><blockquote>德特里克表示：“我们坚信，新高是值得拥抱的，而不是害怕的，历史表明，新高往往会成群结队地出现——今年到目前为止，情况确实如此。”</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the best month for stocks? Hint: the next four weeks<blockquote>股票最好的月份是哪个月？提示：接下来的四周</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">finance.yahoo</strong><span class=\"h-time small\">2021-11-01 07:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.</p><p><blockquote>如果历史有任何迹象的话，股市创纪录的走势将在未来几周内获得动力。</blockquote></p><p> The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.</p><p><blockquote>假期的开始通常是华尔街一年中的强劲时期，分析师指出，这种模式是保持乐观的理由，即股市在经历了动荡的9月份后将保持在历史高点。</blockquote></p><p> Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.</p><p><blockquote>根据LPL Financial的数据，从历史上看，11月一直是股市一年中表现最好的月份——无论是自1950年以来还是过去十年。</blockquote></p><p> That’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.</p><p><blockquote>这还不是全部。根据股票交易者年鉴，历史表明股市最强劲的六个月是11月至4月。11月也是市场最好的三个月（11月至1月）的第一个月。</blockquote></p><p> Why is November the best?</p><p><blockquote>为什么11月是最好的？</blockquote></p><p> This seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.</p><p><blockquote>这种季节性强势是由多种因素共同造成的。一方面，根据LPL Financial的数据，一年中的最后三个月通常是股市最好的月份，股市平均上涨3.8%。</blockquote></p><p> Strong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.</p><p><blockquote>购物者在假期期间的强劲支出也往往会转化为以消费者为中心的企业的强劲季度。一些分析师还将其归因于假期期间的乐观情绪、年终投资组合调整以及投资者正在度假。</blockquote></p><p> “November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”</p><p><blockquote>LPL Financial首席市场策略师瑞安·德特里克(Ryan Detrick)在给客户的一份报告中表示：“11月是一年中最好的月份，但它似乎并没有你想象的那么受欢迎。”“我们都认为12月是最好的月份，但11月实际上更好，而且很少大张旗鼓。也许这应该是多头的月份，而不是火鸡的月份。”</blockquote></p><p> Wall Street avoids spooky October</p><p><blockquote>华尔街避免幽灵般的十月</blockquote></p><p> While October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.</p><p><blockquote>虽然10月份对投资者来说通常被认为是一个幽灵般的月份，在1929年、1987年的崩盘和2008年全球金融危机期间赢得了坏名声，但今年投资者并没有那么害怕。</blockquote></p><p> After the S&amp;P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.</p><p><blockquote>在标普500 9月份录得自冠状病毒大流行开始以来的最大月度跌幅后，由于有进一步迹象表明企业利润在去年衰退后再次增长，该指数在10月份反弹了6%以上。</blockquote></p><p> “It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.</p><p><blockquote>《股票交易者年鉴》编辑杰夫·赫希(Jeff Hirsch)在给客户的一份报告中表示：“看起来市场已经抵制了‘十月恐惧症’，避免了令人恐惧的崩盘或大屠杀，这些崩盘或大屠杀给这个月带来了坏名声。”</blockquote></p><p> To be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.</p><p><blockquote>可以肯定的是，11月份在熊市期间遭受了打击，主要股指较近期峰值下跌了20%以上。</blockquote></p><p> For instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred</p><p><blockquote>例如，根据股票交易者年鉴，2000年11月是纳斯达克综合指数有记录以来第二糟糕的月份，以科技为重点的指数暴跌近23%。只有1987年10月更糟糕，那是“黑色星期一”股灾发生的时候</blockquote></p><p> Why investors should be optimistic</p><p><blockquote>为什么投资者应该乐观</blockquote></p><p> The U.S. economy&nbsp;slowed substantially from July through September&nbsp;following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.</p><p><blockquote>在经历了一系列障碍后，美国经济从7月到9月大幅放缓，包括COVID-19病例激增、供应链瓶颈、消费者价格上涨以及联邦刺激措施效果减弱。</blockquote></p><p> But with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.</p><p><blockquote>但随着新冠肺炎病例的下降和疫苗接种的增加，大多数经济学家认为，在从大流行引发的衰退中仍然强劲的复苏中，疲软表现出疲软，预计今年最后几个月将出现健康反弹。</blockquote></p><p> There are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.</p><p><blockquote>有迹象表明，由于强劲的季节性趋势、好于预期的企业盈利以及COVID-19病例下降，今年最后几个月华尔街可能会出现更多上涨。市场广度也有所改善，这意味着更多股票参与涨势，这是市场健康强劲的标志。</blockquote></p><p> Jobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.</p><p><blockquote>最近几周，申请失业救济人数也在稳步下降，最近申请失业救济人数自冠状病毒大流行开始以来首次降至250万以下。</blockquote></p><p> After suffering its first 5% pullback of 2021 in early October, the S&amp;P 500 has come roaring back and closed at a record high on October 21. The S&amp;P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.</p><p><blockquote>在10月初经历了2021年首次5%的回调后，标普500卷土重来，并于10月21日收于历史新高。标普500指数今年迄今已上涨超过20%，一路上创下50多个历史新高。</blockquote></p><p> That could be a positive sign for investors in the coming months. The past seven times the S&amp;P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.</p><p><blockquote>这对未来几个月的投资者来说可能是一个积极的信号。LPL Financial的数据显示，过去七次标普500在第四季度之前上涨了15%，最后一个季度每次都上涨了5.8%。</blockquote></p><p> “We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.</p><p><blockquote>德特里克表示：“我们坚信，新高是值得拥抱的，而不是害怕的，历史表明，新高往往会成群结队地出现——今年到目前为止，情况确实如此。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html\">finance.yahoo</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150912013","content_text":"The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.\nThe start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.\nHistorically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.\nThat’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.\nWhy is November the best?\nThis seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.\nStrong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.\n“November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”\nWall Street avoids spooky October\nWhile October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.\nAfter the S&P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.\n“It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.\nTo be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.\nFor instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred\nWhy investors should be optimistic\nThe U.S. economy slowed substantially from July through September following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.\nBut with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.\nThere are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.\nJobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.\nAfter suffering its first 5% pullback of 2021 in early October, the S&P 500 has come roaring back and closed at a record high on October 21. The S&P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.\nThat could be a positive sign for investors in the coming months. The past seven times the S&P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.\n“We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":998,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829176459,"gmtCreate":1633483560669,"gmtModify":1633483597604,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Rise","listText":"Rise","text":"Rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829176459","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858779922,"gmtCreate":1635126069049,"gmtModify":1635126708192,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Watch closely","listText":"Watch closely","text":"Watch closely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858779922","repostId":"2178808449","repostType":4,"isVote":1,"tweetType":1,"viewCount":1389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":813210525,"gmtCreate":1630204256867,"gmtModify":1704956983353,"author":{"id":"3583403892979837","authorId":"3583403892979837","name":"AhTong","avatar":"https://static.tigerbbs.com/6271e61474eeec93d63201296d59cb72","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583403892979837","idStr":"3583403892979837"},"themes":[],"htmlText":"Up up up","listText":"Up up up","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/813210525","repostId":"1162964424","repostType":4,"repost":{"id":"1162964424","kind":"news","pubTimestamp":1630111098,"share":"https://www.laohu8.com/m/news/1162964424?lang=zh_CN&edition=full","pubTime":"2021-08-28 08:38","market":"us","language":"en","title":"Apple Stock: How It Could Be A Great Inflation Play<blockquote>苹果股票：它如何成为一场伟大的通胀游戏</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1162964424","media":"TheStreet","summary":"Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.IPhone users thinking of upgrading their devices this year  should expect to reach deeper into their pockets. DigiTimes has reported that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.Bad news for consumers could be great news for Apple stock investors. If the price increase is con","content":"<p>Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.</p><p><blockquote>由于某些组件的价格上涨，苹果的iPhone 13可能会让消费者花费更多。这对用户来说是个坏消息，但对苹果股票投资者来说可能是个好消息。</blockquote></p><p> IPhone users thinking of upgrading their devices this year (or those looking to switch to the iOS-based product) should expect to reach deeper into their pockets. DigiTimes has&nbsp;reported&nbsp;that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.</p><p><blockquote>考虑今年升级设备的IPhone用户（或者那些希望转向基于iOS的产品的用户）应该期待更深入地了解他们的口袋。DigiTimes报道称，由于零部件通胀，苹果的iPhone 13可能会在下个月以更高的价格推出。</blockquote></p><p> Bad news for consumers could be great news for Apple stock&nbsp;investors. If the price increase is confirmed, it provides evidence that AAPL might be a great inflation play during these times of worry over rising producer and consumer prices.</p><p><blockquote>对消费者来说是个坏消息，对苹果股票投资者来说可能是个好消息。如果价格上涨得到证实，这将提供证据表明，在人们担心生产者和消费者价格上涨的时期，苹果公司可能会成为一个巨大的通胀工具。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d6f4ac9ebc1b90072340731dc5c1e613\" tg-width=\"1240\" tg-height=\"698\" referrerpolicy=\"no-referrer\"><span>Figure 1: Apple's iPhone 12 Pro.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果的iPhone 12 Pro。</span></p></blockquote></p><p> <b>What happened?</b></p><p><blockquote><b>怎么回事？</b></blockquote></p><p> The iPhone is already considered a pricey tech gadget that can cost as much as $1,400 for the fully loaded, higher-end 12 Pro Max model in the US (see figure below). Due to this year’s components shortage, chip maker TSMC may raise its part prices to Apple by 3% to 5%, which could lead to a similar increase in the price of the yet-to-be-announced iPhone 13.</p><p><blockquote>iPhone已经被认为是一款昂贵的科技产品，在美国，满载的高端12 Pro Max机型售价高达1400美元（见下图）。由于今年的零部件短缺，芯片制造商台积电可能会将其对苹果的零部件价格提高3%至5%，这可能会导致尚未公布的iPhone 13价格出现类似上涨。</blockquote></p><p> It is unlikely that one of the largest and most successful consumer product companies in the world would try to raise prices without confidence that doing so does not impact demand for the new iPhone substantially. Apple can probably afford to hike prices because the company understands the value and the appeal of its luxury brand.</p><p><blockquote>世界上最大、最成功的消费品公司之一不太可能试图提高价格，而不相信这样做不会对新iPhone的需求产生实质性影响。苹果或许有能力提高价格，因为该公司了解其奢侈品牌的价值和吸引力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0140b9b68bb9eb5dd7e88aaff384785d\" tg-width=\"707\" tg-height=\"370\" referrerpolicy=\"no-referrer\"><span>Figure 2: iPhone 12 Pro on Apple's store.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：苹果商店上的iPhone 12 Pro。</span></p></blockquote></p><p> <b>A quote from Jim Cramer</b></p><p><blockquote><b>引用吉姆·克莱默的话</b></blockquote></p><p> One of the most concerning headwinds to stocks in the foreseeable future is the possibility of inflation eroding corporate margins and leading to higher interest rates in 2021-2022. But should producer and consumer prices spike, not all stocks will be impacted equally.</p><p><blockquote>在可预见的未来，股市最令人担忧的阻力之一是通胀可能侵蚀企业利润率并导致2021-2022年利率上升。但如果生产者和消费者价格飙升，并非所有股票都会受到同等影响。</blockquote></p><p> Generally speaking, companies with strong pricing power that are able to pass on the higher production costs to consumers will likely outperform. This is a point that&nbsp;Mad Money’s Jim Cramer has made recently. Here is his quote:</p><p><blockquote>一般来说，拥有强大定价权、能够将较高的生产成本转嫁给消费者的公司可能会表现出色。这是Mad Money的吉姆·克莱默(Jim Cramer)最近提出的观点。以下是他的名言：</blockquote></p><p>   “When you try to think of what’s working in this market... I want you to ask yourself, would you be insensitive to a price increase if the company put one through? [What are] the companies that can raise prices without infuriating you? Go buy their stocks.”  <b>The impact to the P&amp;L</b></p><p><blockquote>“当你试图思考这个市场上什么在起作用时……我想让你问问自己，如果公司提价，你会对提价麻木不仁吗？有哪些公司可以提价而不会激怒你？去买他们的股票。”<b>对损益的影响</b></blockquote></p><p> Are higher prices a good or a bad thing for a company’s financial performance? The answer is nuanced and depends on a few factors.</p><p><blockquote>价格上涨对公司的财务业绩是好事还是坏事？答案是微妙的，取决于几个因素。</blockquote></p><p> Holding all else constant, higher prices also mean higher revenues (think of the formula for sales: price times quantity). If the increase in price is decoupled from an increase in product or operating costs, then the hike also helps to boost margins – thus profits as well.</p><p><blockquote>在其他条件不变的情况下，更高的价格也意味着更高的收入（想想销售公式：价格乘以数量）。如果价格上涨与产品或运营成本的增加脱钩，那么涨价也有助于提高利润率，从而提高利润。</blockquote></p><p> However, “holding all else constant” is not how the world really works. A change in price tends to have an impact on a few key variables, most important of which is demand. If higher prices do not impact units sold by much or at all, this is great news for revenues and, most likely, earnings.</p><p><blockquote>然而，“保持其他一切不变”并不是世界真正的运作方式。价格的变化往往会对一些关键变量产生影响，其中最重要的是需求。如果更高的价格不会对售出的单位产生太大影响或根本没有影响，那么这对收入以及最有可能的盈利来说是个好消息。</blockquote></p><p> The other piece to consider is whether the price hike fully or only partially offsets higher costs. Assuming the latter, revenues can still benefit without a corresponding positive effect on margins and profits. The complexity presented by the many moving parts makes it hard to determine with certainty how a more expensive iPhone may impact Apple’s financial statements in the future.</p><p><blockquote>另一个需要考虑的问题是价格上涨是否完全或仅部分抵消了更高的成本。假设是后者，收入仍然可以受益，而不会对利润率和利润产生相应的积极影响。许多移动部件所呈现的复杂性使得很难确定更昂贵的iPhone未来可能会如何影响苹果的财务报表。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: How It Could Be A Great Inflation Play<blockquote>苹果股票：它如何成为一场伟大的通胀游戏</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: How It Could Be A Great Inflation Play<blockquote>苹果股票：它如何成为一场伟大的通胀游戏</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-08-28 08:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.</p><p><blockquote>由于某些组件的价格上涨，苹果的iPhone 13可能会让消费者花费更多。这对用户来说是个坏消息，但对苹果股票投资者来说可能是个好消息。</blockquote></p><p> IPhone users thinking of upgrading their devices this year (or those looking to switch to the iOS-based product) should expect to reach deeper into their pockets. DigiTimes has&nbsp;reported&nbsp;that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.</p><p><blockquote>考虑今年升级设备的IPhone用户（或者那些希望转向基于iOS的产品的用户）应该期待更深入地了解他们的口袋。DigiTimes报道称，由于零部件通胀，苹果的iPhone 13可能会在下个月以更高的价格推出。</blockquote></p><p> Bad news for consumers could be great news for Apple stock&nbsp;investors. If the price increase is confirmed, it provides evidence that AAPL might be a great inflation play during these times of worry over rising producer and consumer prices.</p><p><blockquote>对消费者来说是个坏消息，对苹果股票投资者来说可能是个好消息。如果价格上涨得到证实，这将提供证据表明，在人们担心生产者和消费者价格上涨的时期，苹果公司可能会成为一个巨大的通胀工具。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d6f4ac9ebc1b90072340731dc5c1e613\" tg-width=\"1240\" tg-height=\"698\" referrerpolicy=\"no-referrer\"><span>Figure 1: Apple's iPhone 12 Pro.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：苹果的iPhone 12 Pro。</span></p></blockquote></p><p> <b>What happened?</b></p><p><blockquote><b>怎么回事？</b></blockquote></p><p> The iPhone is already considered a pricey tech gadget that can cost as much as $1,400 for the fully loaded, higher-end 12 Pro Max model in the US (see figure below). Due to this year’s components shortage, chip maker TSMC may raise its part prices to Apple by 3% to 5%, which could lead to a similar increase in the price of the yet-to-be-announced iPhone 13.</p><p><blockquote>iPhone已经被认为是一款昂贵的科技产品，在美国，满载的高端12 Pro Max机型售价高达1400美元（见下图）。由于今年的零部件短缺，芯片制造商台积电可能会将其对苹果的零部件价格提高3%至5%，这可能会导致尚未公布的iPhone 13价格出现类似上涨。</blockquote></p><p> It is unlikely that one of the largest and most successful consumer product companies in the world would try to raise prices without confidence that doing so does not impact demand for the new iPhone substantially. Apple can probably afford to hike prices because the company understands the value and the appeal of its luxury brand.</p><p><blockquote>世界上最大、最成功的消费品公司之一不太可能试图提高价格，而不相信这样做不会对新iPhone的需求产生实质性影响。苹果或许有能力提高价格，因为该公司了解其奢侈品牌的价值和吸引力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0140b9b68bb9eb5dd7e88aaff384785d\" tg-width=\"707\" tg-height=\"370\" referrerpolicy=\"no-referrer\"><span>Figure 2: iPhone 12 Pro on Apple's store.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图2：苹果商店上的iPhone 12 Pro。</span></p></blockquote></p><p> <b>A quote from Jim Cramer</b></p><p><blockquote><b>引用吉姆·克莱默的话</b></blockquote></p><p> One of the most concerning headwinds to stocks in the foreseeable future is the possibility of inflation eroding corporate margins and leading to higher interest rates in 2021-2022. But should producer and consumer prices spike, not all stocks will be impacted equally.</p><p><blockquote>在可预见的未来，股市最令人担忧的阻力之一是通胀可能侵蚀企业利润率并导致2021-2022年利率上升。但如果生产者和消费者价格飙升，并非所有股票都会受到同等影响。</blockquote></p><p> Generally speaking, companies with strong pricing power that are able to pass on the higher production costs to consumers will likely outperform. This is a point that&nbsp;Mad Money’s Jim Cramer has made recently. Here is his quote:</p><p><blockquote>一般来说，拥有强大定价权、能够将较高的生产成本转嫁给消费者的公司可能会表现出色。这是Mad Money的吉姆·克莱默(Jim Cramer)最近提出的观点。以下是他的名言：</blockquote></p><p>   “When you try to think of what’s working in this market... I want you to ask yourself, would you be insensitive to a price increase if the company put one through? [What are] the companies that can raise prices without infuriating you? Go buy their stocks.”  <b>The impact to the P&amp;L</b></p><p><blockquote>“当你试图思考这个市场上什么在起作用时……我想让你问问自己，如果公司提价，你会对提价麻木不仁吗？有哪些公司可以提价而不会激怒你？去买他们的股票。”<b>对损益的影响</b></blockquote></p><p> Are higher prices a good or a bad thing for a company’s financial performance? The answer is nuanced and depends on a few factors.</p><p><blockquote>价格上涨对公司的财务业绩是好事还是坏事？答案是微妙的，取决于几个因素。</blockquote></p><p> Holding all else constant, higher prices also mean higher revenues (think of the formula for sales: price times quantity). If the increase in price is decoupled from an increase in product or operating costs, then the hike also helps to boost margins – thus profits as well.</p><p><blockquote>在其他条件不变的情况下，更高的价格也意味着更高的收入（想想销售公式：价格乘以数量）。如果价格上涨与产品或运营成本的增加脱钩，那么涨价也有助于提高利润率，从而提高利润。</blockquote></p><p> However, “holding all else constant” is not how the world really works. A change in price tends to have an impact on a few key variables, most important of which is demand. If higher prices do not impact units sold by much or at all, this is great news for revenues and, most likely, earnings.</p><p><blockquote>然而，“保持其他一切不变”并不是世界真正的运作方式。价格的变化往往会对一些关键变量产生影响，其中最重要的是需求。如果更高的价格不会对售出的单位产生太大影响或根本没有影响，那么这对收入以及最有可能的盈利来说是个好消息。</blockquote></p><p> The other piece to consider is whether the price hike fully or only partially offsets higher costs. Assuming the latter, revenues can still benefit without a corresponding positive effect on margins and profits. The complexity presented by the many moving parts makes it hard to determine with certainty how a more expensive iPhone may impact Apple’s financial statements in the future.</p><p><blockquote>另一个需要考虑的问题是价格上涨是否完全或仅部分抵消了更高的成本。假设是后者，收入仍然可以受益，而不会对利润率和利润产生相应的积极影响。许多移动部件所呈现的复杂性使得很难确定更昂贵的iPhone未来可能会如何影响苹果的财务报表。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/iphone/apple-stock-how-it-could-be-a-great-inflation-play\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/iphone/apple-stock-how-it-could-be-a-great-inflation-play","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162964424","content_text":"Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.\nIPhone users thinking of upgrading their devices this year (or those looking to switch to the iOS-based product) should expect to reach deeper into their pockets. DigiTimes has reported that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.\nBad news for consumers could be great news for Apple stock investors. If the price increase is confirmed, it provides evidence that AAPL might be a great inflation play during these times of worry over rising producer and consumer prices.\nFigure 1: Apple's iPhone 12 Pro.\nWhat happened?\nThe iPhone is already considered a pricey tech gadget that can cost as much as $1,400 for the fully loaded, higher-end 12 Pro Max model in the US (see figure below). Due to this year’s components shortage, chip maker TSMC may raise its part prices to Apple by 3% to 5%, which could lead to a similar increase in the price of the yet-to-be-announced iPhone 13.\nIt is unlikely that one of the largest and most successful consumer product companies in the world would try to raise prices without confidence that doing so does not impact demand for the new iPhone substantially. Apple can probably afford to hike prices because the company understands the value and the appeal of its luxury brand.\nFigure 2: iPhone 12 Pro on Apple's store.\nA quote from Jim Cramer\nOne of the most concerning headwinds to stocks in the foreseeable future is the possibility of inflation eroding corporate margins and leading to higher interest rates in 2021-2022. But should producer and consumer prices spike, not all stocks will be impacted equally.\nGenerally speaking, companies with strong pricing power that are able to pass on the higher production costs to consumers will likely outperform. This is a point that Mad Money’s Jim Cramer has made recently. Here is his quote:\n\n “When you try to think of what’s working in this market... I want you to ask yourself, would you be insensitive to a price increase if the company put one through? [What are] the companies that can raise prices without infuriating you? Go buy their stocks.”\n\nThe impact to the P&L\nAre higher prices a good or a bad thing for a company’s financial performance? The answer is nuanced and depends on a few factors.\nHolding all else constant, higher prices also mean higher revenues (think of the formula for sales: price times quantity). If the increase in price is decoupled from an increase in product or operating costs, then the hike also helps to boost margins – thus profits as well.\nHowever, “holding all else constant” is not how the world really works. A change in price tends to have an impact on a few key variables, most important of which is demand. If higher prices do not impact units sold by much or at all, this is great news for revenues and, most likely, earnings.\nThe other piece to consider is whether the price hike fully or only partially offsets higher costs. Assuming the latter, revenues can still benefit without a corresponding positive effect on margins and profits. The complexity presented by the many moving parts makes it hard to determine with certainty how a more expensive iPhone may impact Apple’s financial statements in the future.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}